- Abstract:
-
Conventional surgery and radiotherapy for acromegaly have limitations. There are few data on the use of the somatostatin analog octreotide (Oct) as primary medical therapy. An open prospective study of 27 patients with newly diagnosed acromegaly was conducted in nine endocrine centers in the United Kingdom. Twenty patients had macroadenomas, and 7 had microadenomas. For the first 24 wk (phase 1), patients received sc Oct in an initial dose of 100 microg, 3 times daily, increased to 200 micro ...
Expand abstract - Journal:
- The Journal of clinical endocrinology and metabolism
- Volume:
- 87
- Issue:
- 10
- Pages:
- 4554-4563
- Publication date:
- 2002-10-05
- DOI:
- EISSN:
-
1945-7197
- ISSN:
-
0021-972X
- URN:
-
uuid:e7c098b7-99da-4e60-a615-4a0968214544
- Source identifiers:
-
95859
- Local pid:
- pubs:95859
- Language:
- English
- Keywords:
- Copyright date:
- 2002
Journal article
Primary medical therapy for acromegaly: an open, prospective, multicenter study of the effects of subcutaneous and intramuscular slow-release octreotide on growth hormone, insulin-like growth factor-I, and tumor size.
Actions
Authors
Bibliographic Details
Item Description
Terms of use
Metrics
Altmetrics
Dimensions
If you are the owner of this record, you can report an update to it here: Report update to this record